Enhance The Brain Concentration And Antiepileptic Effect Of Drug Lamotrigine By Encapsulating Inside The Chitosan Coated Nanoliposomes For Intranasal Drug Delivery System

Abstract

Most potentially active therapeutic chemicals are unable to reach the brain from the systemic circulation due to the blood brain barrier's (BBB) restricted medication entry. Lamotrigine, an AED that may operate as either an enzyme inducer or an enzyme inhibitor, is routinely used in conjunction with other AEDs, and the goal of this study is to evaluate the magnitude of the impact size of concurrent antiepileptic medication on lamotrigine concentrations. A total of 304 epilepsy patients ranging in age from 18 to 70 were randomly assigned to receive either lamotrigine alone or lamotrigine in combination with either an enzyme inducer, an enzyme inhibitor, or both. Lamotrigine's serum concentrations were determined after single-drug, double-drug, and triple-drug dosing with valproate, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, and topiramate. Higher amounts of valproate led to greater inhibition and higher lamotrigine concentrations. These results may have therapeutic implications for the best dosage of AEDs to use in patient care.